Astellas Pharma Inc.
ALPMYOTCHealthcare● Active
$13.49
+$0.26(+1.97%)
Market Cap$24.2B
P/E Ratio—
52W High$17.35
52W Low$9.11
Astellas Pharma Inc. (ALPMY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALPMY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.268T | $1.912T | $1.604T | $1.519T | $1.296T |
| Cost of Revenue | $0.577T | $0.349T | $0.292T | $0.327T | $0.281T |
| Gross Profit | $1.691T | $1.563T | $1.311T | $1.192T | $1.015T |
| Gross Margin %(computed) | 74.55% | 81.74% | 81.76% | 78.48% | 78.30% |
| Operating Expenses | |||||
| R&D Expenses | $0.334T | $0.328T | $0.294T | $0.276T | $0.246T |
| G&A Expenses | $0.000T | $0.843T | $0.740T | $0.630T | $0.549T |
| Total Operating Expenses | $1.246T | $1.522T | $1.286T | $0.906T | $0.795T |
| Operating Income | $0.445T | $0.041T | $0.026T | $0.285T | $0.156T |
| Operating Margin %(computed) | 19.62% | 2.15% | 1.59% | 18.80% | 12.01% |
| Interest Income | $0.009T | $0.008T | $0.011T | $0.008T | $0.006T |
| Interest Expense | $0.015T | $0.018T | $0.012T | $0.009T | $0.005T |
| Income Before Tax | $0.399T | $0.031T | $0.025T | $0.132T | $0.156T |
| Income Tax Expense | $0.090T | ($0.020T) | $0.008T | $0.034T | $0.033T |
| Net Income | $0.309T | $0.051T | $0.017T | $0.099T | $0.124T |
| Net Margin %(computed) | 13.63% | 2.65% | 1.06% | 6.50% | 9.57% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $172.56 | $28.35 | $9.51 | $54.24 | $67.08 |
| Wtd Avg Shares | 0.002T | 0.002T | 0.002T | 0.002T | 0.002T |
| EBITDA | $0.651T | $0.248T | $0.195T | $0.247T | $0.242T |
| EBITDA Margin %(computed) | 28.72% | 12.97% | 12.15% | 16.26% | 18.63% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · T
Explore more Astellas Pharma Inc. data
About Astellas Pharma Inc. (ALPMY) Income Statement
Astellas Pharma Inc. (ALPMY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, ALPMY reported revenue of $2268.26B, gross profit of $1691.02B (gross margin 74.55%), and net income of $309.12B — a net profit margin of 13.63%.
Frequently asked questions
ALPMY · 4 questionsAstellas Pharma Inc. (ALPMY) reported revenue of $2268.26B for 2026, up 18.6% year-over-year.
ALPMY revenueALPMY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09